610 related articles for article (PubMed ID: 33859638)
21. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
22. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy.
Haupt K; Roggendorf M; Mann K
Exp Biol Med (Maywood); 2002 Apr; 227(4):227-37. PubMed ID: 11910045
[TBL] [Abstract][Full Text] [Related]
23. Live-attenuated bacteria as a cancer vaccine vector.
Toussaint B; Chauchet X; Wang Y; Polack B; Le Gouëllec A
Expert Rev Vaccines; 2013 Oct; 12(10):1139-54. PubMed ID: 24124876
[TBL] [Abstract][Full Text] [Related]
24. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
25. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccination in oncology: current status, opportunities and perspectives.
van den Berg JH; Oosterhuis K; Beijnen JH; Nuijen B; Haanen JB
Curr Clin Pharmacol; 2010 Aug; 5(3):218-25. PubMed ID: 20406167
[TBL] [Abstract][Full Text] [Related]
27. DNA vaccines.
Reyes-Sandoval A; Ertl HC
Curr Mol Med; 2001 May; 1(2):217-43. PubMed ID: 11899073
[TBL] [Abstract][Full Text] [Related]
28. Chemical Strategies to Boost Cancer Vaccines.
Li WH; Li YM
Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
[TBL] [Abstract][Full Text] [Related]
29. Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague.
van der Laan JW
Expert Rev Vaccines; 2005 Feb; 4(1):15-8. PubMed ID: 15757468
[No Abstract] [Full Text] [Related]
30. Preclinical models and technologies to advance nanovaccine development.
Peres C; Matos AI; Moura LIF; Acúrcio RC; Carreira B; Pozzi S; Vaskovich-Koubi D; Kleiner R; Satchi-Fainaro R; Florindo HF
Adv Drug Deliv Rev; 2021 May; 172():148-182. PubMed ID: 33711401
[TBL] [Abstract][Full Text] [Related]
31. Correlates of immune and clinical activity of novel cancer vaccines.
van der Burg SH
Semin Immunol; 2018 Oct; 39():119-136. PubMed ID: 29709421
[TBL] [Abstract][Full Text] [Related]
32. Cytokine gene-engineered vaccines.
Forni G; Boggio K
Curr Opin Mol Ther; 1999 Feb; 1(1):34-8. PubMed ID: 11249681
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
34. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
35. Immunostimulatory colloidal delivery systems for cancer vaccines.
Saupe A; McBurney W; Rades T; Hook S
Expert Opin Drug Deliv; 2006 May; 3(3):345-54. PubMed ID: 16640495
[TBL] [Abstract][Full Text] [Related]
36. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
Vermaelen K
Front Immunol; 2019; 10():8. PubMed ID: 30723469
[TBL] [Abstract][Full Text] [Related]
37. Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.
Goodwin TJ; Huang L
Vaccine; 2017 May; 35(19):2550-2557. PubMed ID: 28385609
[TBL] [Abstract][Full Text] [Related]
38. Improvement of different vaccine delivery systems for cancer therapy.
Bolhassani A; Safaiyan S; Rafati S
Mol Cancer; 2011 Jan; 10():3. PubMed ID: 21211062
[TBL] [Abstract][Full Text] [Related]
39. Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.
Cruz LJ; Rueda F; Simón L; Cordobilla B; Albericio F; Domingo JC
Nanomedicine (Lond); 2014 Apr; 9(4):435-49. PubMed ID: 24910875
[TBL] [Abstract][Full Text] [Related]
40. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
